Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System decreased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating) by 19.4% in the 2nd quarter, Holdings Channel reports. The fund owned 12,992 shares of the company’s stock after selling 3,130 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Axsome Therapeutics were worth $498,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Fairmount Funds Management LLC grew its holdings in Axsome Therapeutics by 402.4% during the 1st quarter. Fairmount Funds Management LLC now owns 942,571 shares of the company’s stock valued at $39,013,000 after purchasing an additional 754,973 shares in the last quarter. US Bancorp DE grew its stake in shares of Axsome Therapeutics by 13,464.6% during the second quarter. US Bancorp DE now owns 262,882 shares of the company’s stock valued at $10,068,000 after acquiring an additional 260,944 shares in the last quarter. Graham Capital Management L.P. increased its position in shares of Axsome Therapeutics by 336.5% during the first quarter. Graham Capital Management L.P. now owns 101,851 shares of the company’s stock worth $4,215,000 after acquiring an additional 78,518 shares during the last quarter. Bellevue Group AG lifted its stake in shares of Axsome Therapeutics by 10.4% in the first quarter. Bellevue Group AG now owns 719,482 shares of the company’s stock worth $29,779,000 after acquiring an additional 67,545 shares in the last quarter. Finally, Endurant Capital Management LP boosted its holdings in Axsome Therapeutics by 80.3% in the first quarter. Endurant Capital Management LP now owns 100,299 shares of the company’s stock valued at $4,151,000 after purchasing an additional 44,670 shares during the last quarter. Hedge funds and other institutional investors own 54.96% of the company’s stock.

Axsome Therapeutics Stock Up 5.5 %

Axsome Therapeutics stock opened at $56.17 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.15 and a current ratio of 4.19. Axsome Therapeutics, Inc. has a one year low of $20.63 and a one year high of $71.98. The company has a 50-day simple moving average of $50.46 and a 200-day simple moving average of $43.25. The firm has a market capitalization of $2.44 billion, a P/E ratio of -13.83 and a beta of 1.75.

Analysts Set New Price Targets

AXSM has been the topic of a number of recent analyst reports. Loop Capital initiated coverage on Axsome Therapeutics in a research report on Tuesday, November 1st. They issued a “buy” rating and a $95.00 target price on the stock. Guggenheim upped their price target on shares of Axsome Therapeutics from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, November 11th. StockNews.com initiated coverage on shares of Axsome Therapeutics in a report on Wednesday, October 12th. They set a “sell” rating for the company. SVB Leerink upped their target price on shares of Axsome Therapeutics from $50.00 to $75.00 in a research note on Monday, August 22nd. Finally, Cowen reduced their target price on Axsome Therapeutics to $125.00 in a report on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.45.

About Axsome Therapeutics

(Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Further Reading

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMGet Rating).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.